Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$120,000.00

Impact of copathology burden on 18F-FDG PET metabolism patterns and cognition of patients with pathology-proven Alzheimer's disease and frontotemporal lobar degeneration

EF 2020-21

Résumé
Background: Alzheimer's disease (AD) is the most common cause of dementia worldwide. Its definitive diagnosis can only be confirmed following death (post-mortem), as it is defined by the presence of specific toxic proteins (pathology) in brain tissue. Nonetheless, clinical criteria as well as recent advances in neuroimaging can inform the diagnosis in living patients presenting alterations of mental functions. However, biomarker evidence for AD pathology has to be interpreted with caution, as it does not necessarily signify that AD is the only or even the main pathological abnormality underlying the symptoms. On the one hand, post-mortem studies have systematically shown that the vast majority of clinically impaired patients with AD pathology also harbor multiple copathologies that likely contribute to their brain degeneration and clinical deficits. Unfortunately, no specific biomarkers currently exist for these pathologies so it is impossible to evaluate the impact of non-AD pathologies on patients with clinical and biomarker-supported AD. On the other hand, mild to moderate levels of AD pathology can sometimes be found in patients presenting with another neurodegenerative disease, such as frontotemporal lobar degeneration (FTLD). However, it is still unclear how the presence of comorbid AD pathology additionally impacts the brain of FTLD patients. Goals: To characterize and compare AD patients presenting with various copathologies (ex: FTLD copathology) and inversely to characterize and compare FTLD patients presenting with AD copathology. Methods and analyses: Subjects will be selected from the UCSF Memory and Aging Center (MAC) Neurodegenerative Brain Bank database, in which the data of 48 AD and 104 FTLD patients is already available. These subjects underwent a cognitive assessment and medical imaging. Contributions: This study will allow us to better interpret the markers and clinical symptoms of these two diseases in order to better guide clinical trials.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
441047
Name
Chapleau Marianne
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Aging
Theme2
Clinical
Prcname2
Allied Health Professionals - Fellowships
Projecttitle
Impact of copathology burden on 18F-FDG PET metabolism patterns and cognition of patients with pathology-proven Alzheimer's disease and frontotemporal lobar degeneration
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Alzheimer'S Disease; Amyloid Imaging; Cognition; Fdg-Pet; Frontotemporal Lobar Degeneration; Neurodegenerative Diseases; Pathology; Pet Imaging
Abstract
Background: Alzheimer's disease (AD) is the most common cause of dementia worldwide. Its definitive diagnosis can only be confirmed following death (post-mortem), as it is defined by the presence of specific toxic proteins (pathology) in brain tissue. Nonetheless, clinical criteria as well as recent advances in neuroimaging can inform the diagnosis in living patients presenting alterations of mental functions. However, biomarker evidence for AD pathology has to be interpreted with caution, as it does not necessarily signify that AD is the only or even the main pathological abnormality underlying the symptoms. On the one hand, post-mortem studies have systematically shown that the vast majority of clinically impaired patients with AD pathology also harbor multiple copathologies that likely contribute to their brain degeneration and clinical deficits. Unfortunately, no specific biomarkers currently exist for these pathologies so it is impossible to evaluate the impact of non-AD pathologies on patients with clinical and biomarker-supported AD. On the other hand, mild to moderate levels of AD pathology can sometimes be found in patients presenting with another neurodegenerative disease, such as frontotemporal lobar degeneration (FTLD). However, it is still unclear how the presence of comorbid AD pathology additionally impacts the brain of FTLD patients. Goals: To characterize and compare AD patients presenting with various copathologies (ex: FTLD copathology) and inversely to characterize and compare FTLD patients presenting with AD copathology. Methods and analyses: Subjects will be selected from the UCSF Memory and Aging Center (MAC) Neurodegenerative Brain Bank database, in which the data of 48 AD and 104 FTLD patients is already available. These subjects underwent a cognitive assessment and medical imaging. Contributions: This study will allow us to better interpret the markers and clinical symptoms of these two diseases in order to better guide clinical trials.
Competitiondate
202012
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Chapleau, Marianne
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~